Webinar
How to get the best out of RAG for scientific research
January 22, 2025 03:30 PM Europe/London
The webinar will be held Weds Jan 22 2025 at 3.30-4.30pm GMT, 10.30-11.30am EST, 7.30-8.30am PST, 4.30-5.30pm CET
Many biopharma organisations are struggling with the challenges of poorly implemented GenAI and RAG, often related to not being able to clearly reference where information has come from and thus not being able to trust the resulting data. How can data quality be better prioritised in RAG implementation?
This fireside chat webinar features data science in pharma experts speaking to the perspective of implementing RAG for biopharma research. Daniel Jamieson, CEO at Biorelate and Michaël Ughetto (Director of AI Strategy & Innovation for R&D IT at AstraZeneca) will dive into the present and future of RAG in scientific research settings. This is a not-to-miss discussion for anyone in data science at biopharma organisations seeking to optimise their RAG strategy and usage.
Daniel Jamieson
Dr. Daniel Jamieson is the founder and CEO of Biorelate Ltd., a cutting-edge tech-bio at the forefront of using data science to revolutionise pharmaceutical research. Under his leadership, Biorelate has become a world leader in leveraging advanced data science
methods to extract critical knowledge from vast amounts of pharmaceutical data and
literature, significantly enhancing the discovery of novel biopharmaceuticals.
Michaël Ughetto
Michaël Ughetto is a Director of AI Strategy & Innovation for R&D IT at AstraZeneca, where he leads the team responsible for the Biological Insights Knowledge Graph (BIKG). Coming from a background in experimental particle physics, Michaël has shifted his focus to data science and machine learning, applying these skills to drug discovery. Since joining AstraZeneca in 2019, he has worked on using recommender systems and graph data science to help choose drug targets. His current work involves creating new tools to help with different stages of drug development, from finding targets to discovering biomarkers. Last year, the BIKG team released the first version of its AI-assisted chatbot for AstraZeneca’s R&D scientists, making it easier and faster to access knowledge from BIKG, the literature, and many other data sources.